Skip to main content
Premium Trial:

Request an Annual Quote

Sage Bionetworks to Model Cancer Pathway Data for AstraZeneca

Premium

Sage Bionetworks and AstraZeneca have begun a collaboration to apply Sage's pathway modeling technology to provide insight into new cancer therapeutics.

Under the terms of the partnership, announced this week, Sage will contribute its computer modeling methodology and AstraZeneca will provide oncology expertise and data on its proprietary compounds.

Financial terms of the deal were not disclosed.

The collaboration is the third that Sage has announced with a major pharmaceutical firm since it was founded in 2009, adding to existing agreements with Merck and Pfizer (BI 3/31/2010).

The collaboration with AstraZeneca will focus on cancer regulatory pathways and will draw from large cancer genomic datasets and predictive disease models developed at Sage.

The partners said in a statement that the project "will potentially provide data-driven rationales for prioritizing therapeutic targets," and might also identify cancer patient subpopulations that would most likely benefit from new treatments.

Susan Galbraith, vice president and head of the Oncology Innovative Medicines Unit at AstraZeneca, said that the company aims to work with Sage "to build realistic, predictive models of cancers to expand our current understanding of these diseases and potentially harness that knowledge into new target identification, portfolio positioning, and patient selection."

Stephen Friend, president of Sage, said that the computational models that arise from the collaboration will be placed in the non-profit's public repository following the completion of the project.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.